mPharma is a West African pharmaceutical technology company founded in 2013 by Gregory Rockson, a Ghanaian entrepreneur, in Accra. While not Kenyan-founded, mPharma's expansion into Kenya made it one of the most significant healthtech companies operating in the East African market, and its approach to fixing Africa's broken pharmaceutical supply chain offered lessons applicable across the continent's healthcare landscape.
The company's founding thesis addressed a paradox: millions of Africans could not afford essential medications, yet pharmaceutical supply chains were so inefficient that drugs were simultaneously overpriced and undersupplied. Markup chains of 200 to 400 percent were common between manufacturer and patient. Pharmacies in Nairobi's low-income areas frequently ran out of basic medications - antibiotics, antimalarials, chronic disease drugs - because they could not afford to hold adequate inventory. Meanwhile, drugs expired on warehouse shelves because demand forecasting was rudimentary.
mPharma attacked this problem through a managed pharmacy model. The company partnered with independent pharmacies, providing them with inventory management software, data-driven demand forecasting, and access to bulk-purchased medications at lower prices. In exchange, mPharma took a share of revenue. The company essentially functioned as a technology-enabled pharmaceutical distributor, using data to optimise the supply chain from manufacturer to patient.
In Kenya, mPharma entered the market through acquisitions and partnerships with pharmacy chains, building a network of managed pharmacies across Nairobi and other major cities. The Kenyan pharmaceutical market was attractive - valued at over $1 billion annually, growing rapidly, and characterised by the same supply chain inefficiencies that mPharma had targeted in Ghana and Nigeria. Kenya's relatively developed mobile payment infrastructure, anchored by M-Pesa, also enabled mPharma to implement digital payment solutions for patients, including instalment payment plans for expensive medications.
The company raised over $65 million from investors including the International Finance Corporation, Social Capital, 4DX Ventures, and the Bill and Melinda Gates Foundation's Strategic Investment Fund. Rockson's fundraising success reflected investor enthusiasm for the healthcare-meets-technology thesis in Africa - a market where healthcare spending was growing rapidly but distribution infrastructure remained pre-digital.
mPharma's model in Kenya intersected with broader trends in Kenyan healthtech, including the growth of telemedicine during COVID-19, the expansion of the National Health Insurance Fund (NHIF), and government efforts to achieve universal health coverage. The company's data on drug consumption patterns, pricing, and demand across its pharmacy network constituted one of the most comprehensive pharmaceutical datasets in East Africa - potentially valuable for public health planning, drug manufacturers, and health insurers.
The challenges were significant. Kenya's pharmaceutical regulatory environment, overseen by the Pharmacy and Poisons Board, imposed requirements that varied from West African markets where mPharma had operated longer. Competition from established pharmaceutical distributors and pharmacy chains was fierce. And the managed pharmacy model required significant upfront investment in relationships, technology integration, and inventory - making profitability a long-term proposition.
See Also
Sources
- Bright, Jake. "mPharma Raises $35M to Expand Pharmaceutical Supply Chain Tech Across Africa." TechCrunch, 2021.
- Adegoke, Yinka. "How mPharma Is Fixing Africa's Broken Drug Supply Chain." Rest of World, 2020.
- Rocksbon, Gregory. "Building a Pan-African Pharmacy Network." Interview, How We Made It in Africa, 2019.
- International Finance Corporation. "Investing in Health: mPharma and Pharmaceutical Access in Africa." IFC Case Study, 2021.